# Lantheus Medical Imaging: Phase 3 study in Prostate Cancer (408 participants)

**Score:** 65/100

| Field | Value |
|---|---|
| Sponsor | Lantheus Medical Imaging |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | Dose Optimization and Diagnostic Performance in Prostate Cancer (SPARROW [Staging Prostate Cancer With Advanced RM2 Radiotracer Oncologic Workup]) |
| NCT ID | NCT07831824 |
| Phase | Phase 3 |
| Status | recruiting |
| Conditions | Prostate Cancer |
| Intervention types | drug |
| Target enrollment | 408 |
| Site countries | United States |
| Posted | 2026-09-21 |
| Planned start | 2026-09-30 |
| Event | Newly registered study |
| Event date | 2026-09-21 |

## Why this score
- Industry sponsor (buys outsourced services).
- Phase 3: multi-site, larger budget.
- 408 participants planned.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07831824). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.